132 related articles for article (PubMed ID: 38447209)
1. Liver transplantation for advanced hepatocellular carcinoma after downstaging with consequential lenvatinib, transcatheter arterial chemoembolization and camrelizumab.
Peng W; Wu Y; Zhang X; Li C; Shen J; Chen W; Li Q; Ma J; Yang Y; Lu W; Liu Z; Sun X; Yang J; Zhou Y; Wen T
Br J Surg; 2024 Mar; 111(3):. PubMed ID: 38447209
[No Abstract] [Full Text] [Related]
2. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
[No Abstract] [Full Text] [Related]
3. Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics.
Wu J; Wu J; Li S; Luo M; Zeng Z; Li Y; Fu Y; Li H; Liu D; Ou X; Lin Z; Wei S; Yan M
Biosci Trends; 2024 Mar; 18(1):42-48. PubMed ID: 38325823
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
Wang K; Wang H; Lv Y; Liu H; Liu J; Zhang Y
Ann Palliat Med; 2021 Jan; 10(1):803-809. PubMed ID: 33545802
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
6. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated.
Li S; Li Y
Hepatol Int; 2024 Apr; 18(2):704-705. PubMed ID: 37943415
[No Abstract] [Full Text] [Related]
7. Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy.
Luo J; Huang Z; Wang M; Li T; Huang J
BMC Gastroenterol; 2022 Mar; 22(1):108. PubMed ID: 35260095
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.
Lu J; Zhang XP; Zhong BY; Lau WY; Madoff DC; Davidson JC; Qi X; Cheng SQ; Teng GJ
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):721-730. PubMed ID: 31387735
[TBL] [Abstract][Full Text] [Related]
10. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
[TBL] [Abstract][Full Text] [Related]
11. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
[TBL] [Abstract][Full Text] [Related]
12. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
Altayar O; Shah R; Chang CY; Falck-Ytter Y; Muir AJ
Gastroenterology; 2022 Mar; 162(3):937-951. PubMed ID: 35210015
[No Abstract] [Full Text] [Related]
13. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.
Yarchoan M; Agarwal P; Villanueva A; Rao S; Dawson LA; Llovet JM; Finn RS; Groopman JD; El-Serag HB; Monga SP; Wang XW; Karin M; Schwartz RE; Tanabe KK; Roberts LR; Gunaratne PH; Tsung A; Brown KA; Lawrence TS; Salem R; Singal AG; Kim AK; Rabiee A; Resar L; Hoshida Y; He AR; Ghoshal K; Ryan PB; Jaffee EM; Guha C; Mishra L; Coleman CN; Ahmed MM
Cancer Res; 2019 Sep; 79(17):4326-4330. PubMed ID: 31481419
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant combined strategy to surgery based on chemoembolization and lenvatinib in hepatocellular carcinoma.
Colón Rodríguez A; Velasco Sánchez E; Rodríguez-Bachiller L; Díaz-Zorita B; López Baena JÁ; Álvarez Luque A; Rincón Rodríguez D; Matilla Peña AM
Gastroenterol Hepatol; 2022; 45(6):490-491. PubMed ID: 34400190
[No Abstract] [Full Text] [Related]
15. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
16. The prime time for management of hepatocellular carcinoma in Hong Kong.
Chan LL; Chan SL
Clin Mol Hepatol; 2023 Apr; 29(2):345-348. PubMed ID: 36907571
[No Abstract] [Full Text] [Related]
17. Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma.
Ishigaki K; Hamada T; Nakai Y; Ishigaki Y; Oyama H; Kanai S; Suzuki T; Nakamura T; Sato T; Hakuta R; Saito K; Saito T; Takahara N; Mizuno S; Kogure H; Tateishi R; Tada M; Koike K
Clin J Gastroenterol; 2020 Aug; 13(4):568-571. PubMed ID: 32242306
[TBL] [Abstract][Full Text] [Related]
18. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis.
Terasawa M; Allard MA; Golse N; Sa Cunha A; Cherqui D; Adam R; Saiura A; Vibert E
Surgery; 2020 Feb; 167(2):425-431. PubMed ID: 31780050
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
[TBL] [Abstract][Full Text] [Related]
20. Downstaging hepatocellular carcinoma prior to liver transplantation.
Gamblin TC; Geller DA
Liver Transpl; 2005 Dec; 11(12):1466-8. PubMed ID: 16315292
[No Abstract] [Full Text] [Related]
[Next] [New Search]